CA
NZ
UK
AU
IND
US
● Bolt Biotherapeutics reported a second-quarter 2026 net loss of about $7.7 million and held about $18.1 million in cash, expected to fund operations into early 2027.
● Aptevo reported a clinical benefit rate of about 87% and a remission rate of about 81% in its RAINIER trial of mipletamig for frontline AML.
● HeartBeam received FDA clearance for its cable-free, synthesized 12-lead ECG technology and is moving toward a U.S. commercial launch.
MetaVia (NASDAQ:MTVA) rose 2.41% to $1.70 at last closing. The clinical-stage biotechnology company developing treatments for obesity and metabolic disease has advanced its lead obesity candidate with encouraging early data, but it remains a small, pre-revenue company with a limited cash runway and a …
Ernexa Therapeutics (NASDAQ:ERNA) fell 3.48% to $4.57 at last closing. The early-stage biotechnology company developing engineered cell therapies for cancer has reported striking preclinical results for its lead program while remaining a pre-revenue, development-stage company advancing toward its first human trials. For investors, the …
Emergent BioSolutions (NYSE:EBS), a company focused on public-health threats and medical countermeasures, reported a quarter that paired a strong revenue beat and sharply higher adjusted EBITDA with a large non-cash impairment and a guidance cut. For investors, the mixed picture warrants a careful look …
Perrigo Company (NYSE:PRGO), a leading provider of consumer self-care and over-the-counter health products, reported a quarter that, while showing lower sales, beat estimates and reaffirmed guidance for a stronger second half. For investors, the question is whether this value-oriented self-care company can deliver the …
Alphatec Holdings (NASDAQ:ATEC), a company focused on spine-surgery technology, has been growing on the strength of rapid revenue growth, narrowing losses and expanding profitability, along with a raisedEarningsoutlook. For investors, the combination of strong top-line momentum and improving margins raises the question of whether …
Imunon (NASDAQ:IMNN), a clinical-stage biotechnology company developing DNA-based immunotherapies, reported compelling clinical data for its lead ovarian-cancer program and steady progress in its pivotal trial. For investors, the question is whether the strength of its data can be realized given the funding constraints typical …
Actinium Pharmaceuticals (NYSE American:ATNM), a developer of targeted radiotherapies for cancer, faces the funding and execution pressures common to small clinical-stage biotech, including a listing-compliance issue. For investors, the question is whether the company's pipeline of radiation-based cancer therapies can advance far enough to …
Please wait processing your request...